Amphastar Pharmaceuticals, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Amphastar Pharmaceuticals, Inc. (AMPH) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of $26.97 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2017-08-09
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was $4.57M, a 50.95% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was $22.40M, a 60.79% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was $14.01M, a 326.10% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-09-30 was $1.30M, a 63.47% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was $38.56M, a 261.01% increase from fiscal 2015.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was $10.68M, a 49.26% decline from fiscal 2014.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was $21.05M, a 32.18% decline from fiscal 2013.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2013 was $31.04M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $26.97M 10-Q · filed 2017-08-09 | $40.98M derived: sum of 3 quarters · filed 2017-08-09 | $42.28M derived: sum of 4 quarters · filed 2017-08-09 |
| 2017-03-31 | $22.40M 10-Q · filed 2017-05-10 | $36.40M derived: sum of 2 quarters · filed 2017-05-10 | $37.70M derived: sum of 3 quarters · filed 2017-05-10 | $47.03M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-12-31 | $14.01M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $15.30M derived: sum of 2 quarters · filed 2017-03-15 | $24.63M derived: sum of 3 quarters · filed 2017-08-09 | $38.56M 10-K · filed 2017-03-15 |
| 2016-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $10.62M derived: sum of 2 quarters · filed 2017-08-09 | $24.55M 10-Q · filed 2016-11-09 | $27.84M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-06-30 | $9.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $23.26M 10-Q · filed 2017-08-09 | $26.54M derived: sum of 3 quarters · filed 2017-08-09 | $30.10M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $13.93M 10-Q · filed 2017-05-10 | $17.22M derived: sum of 2 quarters · filed 2017-05-10 | $20.77M derived: sum of 3 quarters · filed 2017-05-10 | $23.27M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $6.84M derived: sum of 2 quarters · filed 2017-03-15 | $9.34M derived: sum of 3 quarters · filed 2017-03-15 | $10.68M 10-K · filed 2017-03-15 |
| 2015-09-30 | $3.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $6.06M derived: sum of 2 quarters · filed 2016-11-09 | $7.39M 10-Q · filed 2016-11-09 | $19.72M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $3.84M 10-Q · filed 2016-08-09 | $16.16M derived: sum of 3 quarters · filed 2017-03-15 | $29.79M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $1.34M 10-Q · filed 2016-05-10 | $13.66M derived: sum of 2 quarters · filed 2017-03-15 | $27.29M derived: sum of 3 quarters · filed 2017-03-15 | $28.23M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $12.32M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $25.95M derived: sum of 2 quarters · filed 2017-03-15 | $26.89M derived: sum of 3 quarters · filed 2017-03-15 | $21.05M 10-K · filed 2017-03-15 |
| 2014-09-30 | $13.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $14.56M derived: sum of 2 quarters · filed 2015-11-13 | $8.73M 10-Q · filed 2015-11-13 | $17.24M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | $934.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$4.90M 10-Q · filed 2015-08-13 | $3.61M derived: sum of 3 quarters · filed 2016-03-15 | $4.32M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | -$5.83M 10-Q · filed 2015-05-14 | $2.68M derived: sum of 2 quarters · filed 2016-03-15 | $3.39M derived: sum of 3 quarters · filed 2016-03-15 | |
| 2013-12-31 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $9.22M derived: sum of 2 quarters · filed 2016-03-15 | $31.04M 10-K · filed 2016-03-15 | |
| 2013-09-30 | $709.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $22.53M 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | $21.82M 10-Q · filed 2014-08-13 | |||
| 2012-12-31 | -$1.65M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |